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Lassa virus (LASV) is a BSL-4 restricted agent. To allow study of infection by LASV under BSL-2 conditions,
we generated a recombinant virus in which the LASV glycoprotein (Gp) was placed on the backbone of
lymphocytic choriomeningitis virus (LCMV) Cl13 nucleoprotein, Z and polymerase genes (rLCMV Cl13/
LASV Gp). The recombinant virus displayed high tropism for dendritic cells following in vitro or in vivo
infection. Inoculation of immunocompetent adults resulted in an acute infection, generation of virus-
speciﬁc CD8+ T cells and clearance of the infection. Inoculation of newborn mice with rLCMV Cl13/LASV
Gp resulted in a life-long persistent infection. Interestingly, adoptive transfer of rLCMV Cl13/LASV Gp
immune memory cells into such persistently infected mice failed to purge virus but, in contrast, cleared
virus from mice persistently infected with wt LCMV Cl13.
& 2013 Elsevier Inc. All rights reserved.Introduction
Lassa virus (LASV), the agent of a severe and often fatal hemor-
rhagic illness known as Lassa fever (LF), is endemic in West Africa and
estimated to infect more than 300,000 individuals yearly, hospitalizing
100,000 and causing 20,000 or more deaths. LASV has entered Europe
and America (Freedman and Woodall, 1999; Holmes et al., 1990;
Isaacson, 2001; McCormick and Fisher-Hoch, 2002; Schmitz et al.,
2002) via travelers incubating the virus. As a Category A Select Agent,
LASV is a potential bioterrorist threat (Borio et al., 2002).
An early host immune response to LASV is crucial for survival
(Flatz et al., 2010; Geisbert and Jahrling, 2004; McCormick and
Fisher-Hoch, 2002). Infected individuals with viral titers of 9 logs/
ml blood or above, fail to mount an effective innate/adaptive
immune response and invariably die, whereas those with blood
titer of 8 logs of virus or less do respond immunologically with a
T cell response and survive (Schmitz et al., 2002). Earlier we
documented that alpha-dystroglycan (α–DG) was the receptor
for LASV and other Old World arenaviruses like lymphocytic
choriomeningitis virus (LCMV) (Cao et al., 1998; Oldstone and
Campbell, 2011; Spiropoulou et al., 2002). Further, among cells of
the immune system α–DG is preferentially located on DCs (499%
of α–DG in the immune system is found on DCs) (Kunz et al., 2001;ll rights reserved.
or Genetics of Host Defense,
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dstone).Oldstone and Campbell, 2011; Sevilla et al., 2000; Sevilla et al.,
2004). DCs are a preferred target of wild-type (wt) LASV which
impairs DC function (Baize et al., 2004; Baize et al., 2006; Mahanty
et al., 2003; Pannetier et al., 2011).
LASV and LCMV are members of the Old World arenavirus
family and contain a similar two-RNA segment organization, four
viral genes and genome structure (Buchmeier et al., 2007). The
glycoprotein (Gp) and nucleoprotein (NP) are encoded on the short
RNA segment, while the Z matrix protein and L polymerase are
encoded on the long RNA. With the recent advent of a reverse
genetics for the arenaviruses (Emonet et al., 2011; Emonet et al.,
2009) it is possible to construct a recombinant (r) LCMV backbone
expressing the LASV glycoprotein (Gp), thereby allowing the
investigation of LASV Gp binding, cell entry and replication in
the context of a viral infection.
Utilizing the backbone of LCMV Armstrong (ARM) 53B, a
recombinant virus expressing LASV Gp (Josiah strain) was made
by Rojek and colleagues to study LASV Gp-mediated cell entry
(Rojek et al., 2008). They discovered that LASV entered cells by a
unique endocytic pathway distinct from the clathrin-dependent
endocytosis used by pathogenic New World arenaviruses. How-
ever, this recombinant was not suitable for in vivo animal studies
and thus not useful for dissecting LASV pathogenesis. For that
reason we turned to use of LCMV Cl13 as the backbone for
constructing rLCMV/LASV Gp.
The parental LCMV ARM and its variant strain LCMV Cl13 differ
from each other by six nucleotides and three amino acids of which
only two, one in the Gp spike at aa 260 (ARM/Cl13: Phe/Leu) and
one in the polymerase gene aa 1079 (ARM/Cl13: Lys/Glu) deter-
mine heightened entry into DCs (Gp1 Leu) and heightened
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LCMV ARM. Further, these two amino acid differences determine
whether an acute viral infection is controlled by cytotoxic T (CTL)
cells (ARM) or whether an inadequate generation of T cells occurs
followed by their exhaustion occurs leading to viral persistence
(Cl13) (Barber et al., 2006; Brooks et al., 2006; Wherry, 2011; Zajac
et al., 1998). To take advantage of the enhanced replication of
LCMV Cl13 in DCs to study LASV Gp-mediated pathogenesis, we
used reverse genetics to construct a novel rLCMV Cl13/LASV Gp
using the Cl13 backbone.
Here we report that the rLCMV Cl13/LASV Gp replicates in
multiple tissues of adult mice and induces the generation of robust
virus-speciﬁc CD8+ CTLs. Removal of immune cells by use of Rag2−/−
mice in which lymphoid T and B cells are genetically depleted
enhances viral replication and leads to persistent infection. rLCMV
Cl13/LASV Gp replicates to considerable levels in plasmacytoid
(p) DCs as well as conventional (c) DCs both in vitro and in vivo.
Further, inoculation of newborn mice or breeding of rLCMV Cl13/
LASV Gp infected mice, both called virus carrier mice, leads to a life-
long persistent virus infection. Interestingly, adoptive transfer of
memory T and B cells harvested from rLCMV Cl13/LASV Gp infected
mouse spleens failed to clear the persistent infection of such virus
carrier mice. However, similar immune memory cells could purge
virus from mice persistently infected with LCMV Cl13. Hence, the
rLCMV Cl13/LASV Gp provides a useful tool to study LASV patho-
genesis in a small mouse model for acute and persistent infections
in a BSL-2 setting.Results
Polymerase of LCMV Cl13 provides enhanced replication of LCMV
when compared to the polymerase of LCMV ARM
Our ﬁrst series of experiments determined the efﬁciency of
LCMV replication comparing the polymerase of LCMV Cl13 with
that of LCMV ARM. The L RNA which contains the Z gene and the
polymerase gene from LCMV ARM or from LCMV Cl13 was
swapped with the S RNA gene of LCMV Cl13 or LCMV ARM,
respectively, as previously reported (Popkin et al., 2011; Rojek
et al., 2008). Since the other gene residing on the L RNA, the Z gene
and its protein, is identical between LCMV Cl13 and LCMV ARM,
we were essentially evaluating the difference provided by the
single amino acid mutation at aa 1079 of Glu for LCMV Cl13
compared to Lys for LCMV ARM. Utilizing cloned established
murine dendritic cell lines P4H1 and 9 M (Nayak, Schmedt,
Sullivan, and Oldstone, manuscript in preparation 2013), we noted
that reassorted virus containing the polymerase of LCMV Cl13
replicated 1.5 to 2 logs greater than did the recombinant virus
containing the polymerase of LCMV ARM (Fig. 1, Panels A and B).
Interestingly, despite being linked to the Gp1 of the S RNA of LCMV
ARM which is decidedly inferior for attachment and entry com-
pared to Gp1 of LCMV Cl13 (Sullivan et al., 2011), the replication of
S ARM/L Cl13 was equivalent to the amount of infectious virus
produced by the wild-type LCMV Cl13 (S Cl13/L Cl13) (Fig. 1A,B),
again revealing the greater efﬁciency in replication of LCMV Cl13
polymerase. These results lead us to generate and characterize a
recombinant LCMV Cl13 expressing the envelope Gp of LASV
Josiah strain (rLCMV Cl13/LASV Gp).
Generation and characterization of rLCMV Cl13/LASV Gp
To be able to investigate LASV at BSL-2 level in the context of a
productive infection outside of BSL-4 facility, we utilized published
reverse genetics technology to generate a recombinant LCMV Cl13
where the LASV Gp substituted for LCMV Cl13 Gp (Rojek et al.,2008). Brieﬂy, BHK cells were co-transfected with plasmids pCL
and pCNP, together with plasmids that allowed for Pol I-mediated
intracellular synthesis of the L and S RNA species. We infected
Vero and A549 cells and collected supernatants at 48, 72, and 96 h
post-infection to test for presence of replicating infectious rLCMV
Cl13/LASV Gp (Fig. 1: C,D). The infection kinetics of rLCMV Cl13/
LASV Gp virus were similar to that of the parental LCMV Cl13.
Furthermore, infecting the P4H1 DC line with rLCMV Cl13/LASV Gp
resulted in a similar infection to that of Cl13 (Fig. 1D), with 1.5 to
2 logs greater replication than LCMV ARM. Similar enhanced
replication of 1–2 logs with viruses containing the polymerase of
Cl13 over those with polymerase of ARM occurred in 9 M cloned
DCs (data not shown). Interestingly this enhanced replication of
Cl13 and Cl13 polymerase-containing viruses, while being
observed in DC lines, was not observed in VeroE6 (Fig. 1C) or
A549 and BHK cells (data not shown).
Alpha-dystroglycan (α-DG) has been shown to be the receptor for
LASV (Cao et al., 1998; Spiropoulou et al., 2002). We next determined
whether the infection with rLCMV Cl13/LASV Gp proceeded through
α-DG by incubating the viruses with soluble α-DG prior to initiating
infection. Previously we demonstrated that LCMV Cl13 entry into
cells bearing α-DG on their surfaces was blocked in a dose–depen-
dent manner by soluble α-DG (Cao et al., 1998) and virus entry was
dependent on the Gp of Cl13 (Sullivan et al., 2011). Similar blunting
occurred when soluble α-DG was incubated with rLCMV Cl13/LASV
Gp (Fig. 1E), while titers of virus produced were dependent on α-DG
blockade (Fig. 1F) indicating that the recombinant virus bearing LASV
Gp can be used at BSL-2 level for LASV Gp-mediated binding, entry,
and in vitro replication studies.
Replication of rLCMV Cl13/LASV Gp in vivo in adult mice
We next injected rLCMV Cl13/LASV Gp into adult immunocom-
petent H-2b C57BL/6 mice and studied viral replication in vivo.
Employing a wide dose range from 2105 PFU intraperitoneally
(i.p.) to 2106 and 4106 PFU intravenously (i.v.) of rLCMV Cl13/
LASV Gp, we noted limited viral replication (PFU/gm tissue) in
liver, spleen, kidney, and sera (PFU/ml) (Table 1A—viral dose
indicated). Tissue and serum viral titers dropped signiﬁcantly by
1 to 3 logs between day 5 post-infection (PI) and day 7/8 PI with
the majority of mice completely purging virus at this time. These
results suggested the likelihood of a strong antiviral T-cell
response limiting viral replication and clearing the acute infection.
To test this possibility we utilized Rag2−/− mice on the same
C57BL/6 background inoculated with 4106 PFU of rLCMV Cl13/
LASV Gp. As shown in Table 1A, Rag2−/− mice exhibited an increase
in tissue and serum viral titers from day 5 to day 7/8, indicating
that the immune response cleared the infection.
Low viral titers in C57BL/6 mice precluded the ability to detect
viral antigens in most tissues while, in contrast, infection of Rag2−/−
mice yielded signiﬁcant expression of viral antigen in tissues
(Table 1B). Of interest was the location of viral antigen at day 5 to
the marginal zone of the white pulp of the spleen. This anatomical
location of recombinant LCMV containing the LASV Gp is identical
to that observed earlier (Sevilla et al., 2004; Smelt et al., 2001)
which was dependent on the Gp of LCMV Cl13. Thus, early during
infection LASV Gp mimics LCMV Cl13 Gp on entry in the marginal
zone and into white pulp DCs (Table 1B, lower left panel) which is
dependent on expression of αDG on DCs (Oldstone and Campbell,
2011; Sevilla et al., 2000; Sevilla et al., 2004; Smelt et al., 2001;
Sullivan et al., 2011).
Dendritic cells (DCs) are permissive to rLCMV Cl/LASV Gp infection
We next infected groups of four Rag2−/− mice with rLCMV Cl13/
LASV Gp and focused on rLCMV Cl13/LASV Gp infection of DCs.
Fig. 1. The growth of reassortant viruses in the P4H1 (A) and 9 M (B) cloned DC lines is shown. Viruses containing the polymerase of LCMV Cl13 (red diamonds, green
squares) replicated to 1–2 logs higher titer than those bearing the polymerase of LCMV ARM (orange circles, black triangles). Data points shown are the average of three
independent experiments, and the standard deviation is plotted as error bars for each point (po0.01 for all data points). (C) The growth of rLCMV Cl13/LASV Gp virus (open
circles) and LCMV Clone 13 (solid circles) is shown in VeroE6 cells. Cells were infected with an MOI of 0.1 of each virus, and viral titer in 100 μL supernatant was analyzed by
immune focus assay. Points are mean7standard deviation of focus-forming units per mL (FFU/mL) from three independent measurements. (D) Growth of rLCMV Cl13/LASV
Gp in the P4H1 DC line is similar to that of LCMV Cl13, and two logs higher than LCMV ARM. The growth follows the pattern for LCMV viruses containing the Cl13
polymerase. (E) Immunoﬂuorescent staining of BHK-21 cells infected with virus that was preincubated with either PBS or 100 nM soluble α–DG for 20 min prior to infection.
Infection was done at an MOI of 0.1, and staining of ﬁxed cells was performed 48 h post-infection. (F) Virus titers were measured 48 h post-infection in the supernatant of
BHK-21 cells infected with virus (MOI¼0.1) that was pre-incubated with increasing concentrations of soluble α–DG. Both Clone 13 and rLCMV Cl13/LASV Gp are blocked in a
dose-dependent manner by α–DG.
A.M. Lee et al. / Virology 442 (2013) 114–121116Five and eight days post-infection, both plasmacytoid DCs
obtained from the bone marrow and conventional DCs from the
spleen were assayed for expression of viral antigen using a
monoclonal antibody that detected NP viral antigen and ﬂow
cytometry. As shown in Fig. 2, 29% to 32% of DCs expressed rLCMV
Cl13/LASV Gp virus during acute infection at day 8. Replication of
infectious rLCMV Cl13/LASV Gp from isolated DCs was observed by
infectious center assay (data not shown).
rLCMV Cl13/LASV Gp generates virus-speciﬁc MHC-restricted CTL in
adult immunocompetent mice
We next measured the generation and efﬁciency of virus-
speciﬁc MHC-restricted CTLs. To determine MHC-restriction, we
infected syngeneic H-2b MC57 and allogeneic Balb Cl7 H-2d targets
with an MOI of 1 of rLCMV Cl13/LASV Gp. We ﬁrst insured that
these target cells were infected by and express rLCMV Cl13/LASV
Gp by immunoﬂuorescent staining for the viral NP (Fig. 3A). We
then performed a 51Cr release assay using splenic lymphocytes
from C57BL/6 mice primed 7 days earlier with 1105 PFU of
rLCMV Cl13/LASV Gp i.p. The results showed, in a dose–dependent
manner using different ratios of effector to target cells, that a
robust virus-speciﬁc MHC-restricted CTL response was generated
(Fig. 3B). We then asked what epitopes of rLCMV/LASV Gp were
being recognized by virus-speciﬁc MHC-restricted CTL. As shown
in Fig. 3C, CTLs generated recognize the H-2b immunodominant
NP aa 396-404 peptide coating the H-2b target but not coating the
H-2d target cells, as expected. The LCMV NP epitope is expressed in
both rLCMV/LASV Gp and LCMV and thus CTLs generated against
either of these two viruses recognize NP protein aa 396-404. The
Gp amino acid sequence between LASV Josiah and LCMV ARM isonly 61.5% homologous and LCMV ARM and LCMV Cl13 share the
exact same Gp CTL epitopes. As shown in Fig. 3C, the complete
LCMV Gp expressed using a vaccinia virus (VV) promoter (Whitton
et al., 1988b) is not recognized by CTL generated against rLCMV/
LASV Gp indicating that LASV Gp epitope(s) lie in the 38.5% non-
homologous amino acid sequence between Gp of LASV and that of
LCMV Cl13. As expected CTLs generated against either LCMV Cl13/
LASV Gp or VV expressing whole LCMV NP recognized the NP
epitope 396-404.
The last experiment in this series used tetramers to NP 396-404
to determine the efﬁciency of the generated CTLs in terms of
the number and amount of inﬂammatory cytokines released.
As shown in Fig. 3D, CTLs released interferon-γ, IL-2, and TNF
equivalently when generated against either rLCMV/LASV Gp or the
parental LCMV.rLCMV Cl13/LASV Gp injected into newborn mice results into a life-
long persistent virus carrier model
Inoculation of newborn mice on H-2b (C57BL/6) or H-2d (Balb)
backgrounds with 1104 to 1105 PFU of recombinant virus
intracranially resulted in a lethality of over 85%, while in contrast
inoculation of parental LCMV caused a lethality of o20%. We then
inoculated H-2q (SWR/J) mice with rLCMV Cl13/LASV Gp and had a
survival rate of 475%. Such H-2q virus-inoculated mice carried
virus throughout their life. When sacriﬁced at 42 days PI, analysis
of tissues indicated viral titers of 105 to 106.5 in spleen, kidney,
brain, lung, heart, liver, and sera. Tissues harvested from these
organs, ﬁxed in 4% paraformaldehyde, sectioned and stained with
monoclonal antibody to viral NP antigen revealed widespread
Table 1
(A) displays viral titers and viral antigen expression in C57BL/6 immunocompetent or Rag2−/− mice on the C57BL/6 background depleted of T and B lymphocytes. Titers of
virus were determined by plaque assay and the mean value for at least four individual mice infected with the virus is reported. (B) records expression of viral NP in various
tissues using a monoclonal antibody against the NP (see Materials and Methods). Magniﬁcation of the pictures is 200 or 400 as indicated.
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Table 1B and titers in Table 1A.
We have previously shown that adoptive transfer of MHC-
restricted immune memory cells harvested from the spleen were
able to clear virus from life-long virus carriers whose infection was
initiated similarly at birth with either LCMV ARM or LCMV Cl13
(Berger et al., 2000; Oldstone et al., 1986; Tishon et al., 1993). In
the last series of experiments, we tested whether immune
memory cells generated to rLCMV Cl13/LASV Gp that had demon-
strated robust virus-speciﬁc MHC-restricted CTL activity (Fig. 3)
were able to clear rLCMV Cl13/LASV Gp virus carrier mice. For
these experiments we infected groups of 9 newborn C57BL/6 mice
each with 1103 PFU of either LCMV Cl13 or rLCMV Cl13/LASV Gp
i.c. The lower dose of virus delivered i.c. resulted in increased
survival of the mice following infection. All mice developed a life-
long persistent infection as judged by presence of 104.5 to 105 logs
of virus in their sera. When such persistently infected mice were
30 days old, they each received 2107 immune memory spleno-
cytes i.v. harvested at day 42 post-infection from C57BL/6 mice
immunized with rLCMV Cl13/LASV Gp. Unexpectedly, as shown in
Fig. 4, rLCMV Cl13/LASV Gp persistently infected mice failed to
clear virus when receiving adoptive transferred CTLs generated
against rLCMV Cl13/LASV. Virus persisted as long as 160 days post-
transfer (last time-point analyzed). In contrast, similar CTLs
generated from rLCMV Cl13/LASV successfully purged virus from
all LCMV Cl13 virus carriers by 30 days post-transfer of CTL.Discussion
Here we report the generation of a recombinant LCMV expres-
sing the Gp of LASV and make four observations. First, using the
LCMV backbone, the optimal recombinant virus contains the
polymerase gene of LCMV Cl13 which enhances its replication in
DCs (Fig. 1D), and this rLCMV Cl13/LASV Gp virus shows tropism
and replication for DCs in vivo (Fig. 2). Second, the rLCMV Cl13/
LASV Gp replicates in mouse and generates a robust CTL response
that clears the viral infection (Fig. 3, Table 1). Third, although the
CTLs generated against rLCMV Cl13/LASV Gp are competent in
cleansing virus from an acute infection, they are ineffectual upon
adoptive transfer in terminating a persistent infection initiated by
rLCMV Cl13/LASV Gp (Fig. 4). Lastly the rLCMV Cl13/LASV Gp can
be used at BSL2 for both in vitro and in vivo studies of the role of
LASV Gp in LASV pathogenesis.
Generating genetic reassortant viruses between LCMV ARM
and LCMV Cl13 indicated the advantage of Cl13 polymerase over
that of ARM polymerase for enhanced replication in DCs (Fig. 1A,
B). This led us to construct a recombinant virus bearing LASV Gp
that included the LCMV Cl13 polymerase. The rLCMV Cl13/LASV Gp
demonstrated a dependency of LASV Gp for binding to α–DG and
for cell entry as soluble α–DG was able to blunt infection by a
LCMV Cl13/LASV Gp virus in a dose-dependent fashion. Interesting
was the observation of a difference in viral replication between
LASV Gp recombinant using Cl13 backbone over ARM backbone
Fig. 2. Infection of dendritic cells in vivo by rLCMV Cl13/LASV Gp and by Cl13. Bone
marrow or spleen was harvested from C57BL/6 mice at day 5 and day 8 post-
infection and analyzed for viral antigen in (A) pDCs (CD11blo, CD11c+, B220+) and
(B) cDCs (CD11b+, CD11c+) by intracellular staining for NP antigen and ﬂow
cytometry. As the ﬁgure shows, rLCMV Cl13/LASV Gp and Cl13 viruses can be
found in equivalent amounts in both DC subsets on day 5, and increase signiﬁcantly
by day 8 post-infection. Percentages shows are mean7standard error of the mean
for three independent experiments, with two representative experiments shown.
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including Vero, A549 and BHK cells.
Injection of rLCMV Cl13/LASV Gp into C57BL/6 mice led to an
initial systemic infection that was curtailed by a robust H-2b MHC-
restricted CTL response. Analysis of this response indicated CTLs
were generated against LCMV Cl13 NP as well as LASV Gp amino
acid sequences. The Gp sequences recognized by CTLs generated to
rLCMV Cl13/LASV Gp are distinct from LCMV H-2b restricted
immunodominant Gp aa 33-41, Gp aa 276-286 and subdominant
Gp aa 92-101 and Gp aa 118-125, as the full length LCMV Gp
containing these sequences was not recognized by CTL made to
the recombinant virus bearing LASV Gp when expressed on target
cells using vaccinia virus vectors. The LASV epitopes restricted by
MHC H-2b recognized by CTLs generated to LASV Gp must reside in
the 38.5% of the LASV Gp sequence that is different from the LCMV
Cl13 or ARM Gp. These differences do not comprise any predomi-
nant region of the Gp, but are scattered throughout the sequence.
As such, it is difﬁcult to determine which speciﬁc sequences
within the LASV Gp elicit the CTL responses seen here. Earlier
genetic studies of LCMV genes showed that CTL responses to LCMV
were preferentially generated to the Gp and NP with no detectable
response to the Z protein and only one epitope was noted in the
polymerase protein (Riviere et al., 1986; Whitton et al., 1988a;
Whitton et al., 1988b). As such, LASV Gp H-2b restricted CTL are
likely responsible for the additional level of CTL response to the
recombinant LASV noted over the observed CTL response to NP396-404 alone. Further, the observed generation of a vigorous
antiviral immune response to LASV Gp suggests that the rLCMV
Cl13/LASV Gp might be evaluated as a potential vaccine candidate
against LASV infection.
Persistent lifelong infection can be induced in mice infected
either at birth or in utero with rLCMV Cl13/LASV Gp. This mimics
the naturally occurring LASV persistent infection of most rodents
in LASV endemic areas. Unexpectedly, adoptive transfer of MHC-
restricted immune memory CTLs generated against rLCMV Cl13/
LASV Gp was unable to clear a persistent infection induced by the
recombinant virus. However, MHC-restricted immune memory
CTLs generated to LCMV Cl13 were able to clear the persistent
infection due to rLCMV Cl13/LASV Gp. These results suggest
something unique in the environment of mice infected with the
LASV recombinant virus that prevents clearance of persistent viral
infection. Previous studies utilizing LCMV in which the immuno-
dominant H-2b restricted CTL epitope for NP 396-404 was knocked
out (Lewicki et al., 1995a; Lewicki et al., 1995b) or in which NP
396-404 speciﬁc CTLs were adoptively transferred into mice
indicated the NP 396-404 CTLs were themselves sufﬁcient to
terminate the persistent virus infections. Our analysis of the
functional activity of CTLs generated against NP 396-404 using
either rLCMV Cl13/LASV Gp or CL13 showed that these CTLs were
equally capable of lysing infected targets and expressing the pro-
inﬂammatory cytokines TNFα and IFN-γ (Fig. 3C,D). Thus, it is
unclear why the CTLs generated by recombinant virus infection
were ineffectual in in vivo clearance. Perhaps either an environ-
mental difference in the persistently infected mouse, akin to our
recent report in the TLR7−/− mouse upon LCMV infection (Walsh
et al., 2012), or a requirement for other immune effector cells
differentially elicited by the two viruses is involved.
Lastly, the infection of pDCs or cDCs by LASV Gp-bearing
recombinant virus in vitro and in vivo should allow a biochemical
analysis of virus–DC interactions mediated by the LASV Gp. This is
important as DCs are one of the primary cells infected by wild type
LASV and LASV infection of human DCs has been demonstrated to
alter DC function (Baize et al., 2004; Baize et al., 2006; Mahanty
et al., 2003; Pannetier et al., 2011). Incorporation of the LASV Gp
into the LCMV Clone 13 backbone enabled us to replicate the
tropism of LASV for DCs without having to incorporate any of the
other LASV transcriptional proteins, mitigating the biosafety con-
cerns inherent in LASV work. It is important to note that the
overall immune responses against wild-type LASV in infected
individuals will likely vary from the immune responses against
rLCMV Cl13/LASV Gp shown here owing to the differences
between the other LASV and LCMV proteins (NP, Z, and polymer-
ase). However, the rLCMV Cl13/LASV Gp virus will serve as a useful
tool for uncovering mechanisms of cell binding, entry, infection
and immune subversion initiated by the Gp of LASV in DCs in a
BSL-2 environment rather than the highly restrictive BSL-4 envir-
onment required by work with the wild-type LASV.Materials and methods
Cell lines and reagents
BHK-21 cells were grown in Dulbecco's Modiﬁed Essential
Medium (DMEM) supplemented with 10% Fetal Bovine Serum
(FBS), 100 μg/mL penicillin–streptomycin (Gibco), 2 mM L-glutamine
(Gibco), 0.24% glucose (w/v), and 7% tryptose phosphate broth
solution (Sigma). VeroE6 cells were propagated in Eagle's minimal
essential medium (MEM) supplemented with 7% FBS, 100 μg/mL
penicillin–streptomycin, and 2 mM L-glutamine. MC57 and BALB/c17
cells were propagated in DMEM supplemented with 10% FBS, 100
μg/mL penicillin–streptomycin, and 2 mM L-glutamine. Dendritic cell
Fig. 3. (A) Mouse ﬁbroblasts (MC57, H-2b and Balb cl7, H-2d) were infected with an MOI of 0.1 of rLCMV Cl13/LASV Gp, and were ﬁxed and stained for intracellular viral NP at
the indicated times post-infection. Virus grows equally well in both H-2b and H-2d ﬁbroblasts rendering them excellent target cells. (B) 51Cr release assays done with varying
effector:target ratios for both rLCMV Cl13/LASV Gp and LCMV Clone 13. H-2b targets infected with recombinant virus were killed equally by splenocytes from either
recombinant or Clone-13 infected mice, while Cl13 infected targets were killed more efﬁciently by Cl13 memory splenocytes than recombinant infected memory cells. There
was no killing of allogeneic H-2d targets, as expected. (C) 51Cr release assays with targets infected with either Cl13, recombinant virus, or vaccinia viruses (VV) encoding
LCMV NP, Gp, or the immunodominant NP396-404 epitope. Splenocytes infected with recombinant virus killed targets displaying all the immunogens except the LCMV Gp,
while Cl13 splenocytes were able to kill all the targets, as expected. LASV Gp and Cl13 Gp have 61% homology at the amino acid level, indicating that CTL to LASV Gp likely
recognized LASV Gp epitope(s) differing from Cl13 Gp epitopes. P0 refers to primary inoculation. (D) Expression of pro-inﬂammatory cytokines IFN-γ and TNF-α in CD8+
T-cells infected with either Cl13 or rLCMV Cl13/LASV Gp. Intracellular cytokine staining of splenocytes showed similar levels of both IFN-γ and TNF-α expression between
Cl13 and rLCMV Cl13/LASV Gp. Percentages are shown as mean7standard error of the mean for two independent experiments.
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Fig. 4. Clearance of viral infection by adoptive transfer of memory splenocytes.
Donor B6 mice were infected with 2105 PFU i.p. of either Clone 13 or rLCMV Cl13/
LASV Gp virus, and splenocytes were harvested at day 42 post-infection. After red
blood cell lysis, splenocytes were counted and 2107 total memory splenocytes
were injected i.p. into B6 mice infected at birth with either Clone 13 or rLCMV Cl13/
LASV Gp. Memory splenocytes were matched to the respective viruses; i.e. Clone 13
memory was injected into Clone 13 carrier mice. Serum viral titers were measured
in the mice at the indicated timepoints by plaque assay. As the graph shows, titers
of Clone 13 virus are signiﬁcantly reduced (by 2.5 logs) in the mice by memory
splenocytes at day 14 and totally purged by day 60 post-transfer (black circles). In
contrast, the recombinant rLCMV Cl13/LASV Gp remains in the mouse at high titer
beyond day 160 post-transfer (white circles).
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Institute of the Novartis Foundation) and were propagated in RPMI
1640 medium supplemented with 10% FBS, 100 μg/mL penicillin–
streptomycin, 2 mM L-glutamine, 50 μM β-mercaptoethanol, 1% (v/v)
sodium pyruvate, and 20 μg/mL GM-CSF (Peprotech).
Mouse strains
C57BL/6 and Balb/c mice were obtained from the Rodent
Breeding Colony at The Scripps Research Institute. SWR/J mice
were purchased from The Jackson Laboratory (Bar Harbor, Maine).
Virus strains and stocks
All recombinant viruses used were generated using reverse
genetics technology as described previously (Emonet et al., 2011;
Emonet et al., 2009). To produce rLCMV Cl13/LASV Gp virus,
cloning of the LASV Josiah strain Gp was performed as described
previously for rLCMV ARM/LASV Gp (Rojek et al., 2008). Viral
stocks were generated by passage in BHK-21 cells by infecting at
low multiplicity of infection (MOI¼0.01) for 48 h and collecting
virus-containing culture supernatant followed by cell debris cen-
trifugation at 2000 g for 10 min. at 4 1C. Viral titers were
assessed by immune focus assay (Urata et al., 2010) or by plaque
assay (Sullivan et al., 2011). Recombinant vaccinia viruses expres-
sing the LCMV nucleoprotein or glycoprotein used in chromium
release assays were generated as described previously (Whitton
et al., 1988b).
Virus infections
For cell lines, viral infections were done by adding virus to the
cell culture at a multiplicity of infection (MOI) of 0.1 for 1 h. Virus
was then removed, cells washed, and fresh media was added to the
culture. Viral titers were measured in the supernatants at various
times post-infection. For in vivo studies, mice were injected either
intraperitoneally (i.p.) with a low dose (non-immunosuppressive)or intravenously (i.v.) with a high dose (immunosuppressive) of
virus as indicated. Viral titers were assessed in sera and tissues at
the indicated timepoints post-infection as above. For intracranial
(i.c.) infection, virus was diluted to the required dose in 30 μL ﬁnal
volume, and 30 μL was administered to anesthetized mice by
injection at the midline of the skull using a stepper syringe with a
30 gauge needle and an attached depth stopper.
Generation of persistently infected mouse and adoptive immune
memory T-cell transfer experiments
To generate persistently infected mice, newborn mice (o24 h
old) were injected with 1103 PFU of virus intracranially (i.c.) in
30 μL. Mice and virus titers were weaned at 28 days of age and
virus titers checked in blood obtained from retroorbital bleeding
to ensure mice carried infectious virus. Such virus-carrying mice
received immune splenocytes harvested from adult C57BL/6 J mice
infected with 2105 PFU of virus i.p. Virus carrier mice received
2107 memory splenocytes i.p. in 200 μL PBS. Serum was isolated
from these mice by retroorbital bleeding at the indicated days
post-transfer and assayed for viral titer.
51Chromium release assay
Erythrocyte-depleted single lymphocyte suspensions of cells
obtained from splenocytes of C57BL/6J (H-2b) mice infected with
either LCMV Cl13 or rLCMV Cl13/LASV Gp were used in 51Cr release
assays. Brieﬂy, MHC-haplotype matched MC57 (H-2b) and
unmatched Balb/cl7 (H-2d) cell lines were either infected with
virus (MOI¼1) or coated with peptide corresponding to immuno-
dominant LCMV epitopes for 24 h as indicated in the experiments.
Cells were subsequently labeled with 51Cr for 1 h at 37 1C/5% CO2
and excess unincorporated label was washed away. The labeled
cells were incubated with effector lymphocytes taken from the
infected mice at day 7 post-infection at indicated effector:target
ratios in triplicate for 5 h, and cell lysis was quantiﬁed by assaying
the supernatant for 51Cr using a gamma counter as reported
(Sullivan et al., 2011; Walsh et al., 2012; Welch et al., 2012). Values
are expressed as percent lysis, with an untreated control serving as
no lysis and an NP-40 incubated control serving as 100% lysis. For
assays using recombinant vaccinia viruses expressing the LCMV NP
or GP, target cells were infected with an MOI of 3.
Flow cytometric analysis
All ﬂow cytometric analysis was performed on an LSR-II ﬂow
cytometer (BD Biosciences). Brieﬂy, cells were stained for surface
markers in PBS/1% FBS/0.1% sodium azide buffer prior to any
intracellular staining. Intracellular staining was done using the
BD Cytoﬁx/Cytoperm kit to simultaneously ﬁx and permeabilize
the cells. Cells were incubated with Fc block prior to antibody
staining to reduce background staining from Fc receptors. Anti-
body staining and FACS analysis on DCs were performed as
previously reported (Sullivan et al., 2011; Walsh et al., 2012;
Welch et al., 2012).
Immunoﬂuorescence staining of tissues and cells
Immunoﬂuorescence staining of tissues was performed by col-
lecting tissues and snap-freezing them on dry ice in embedding
medium (OCT, Tissue-Tek). Tissues were cut into 6-μm sections using
a Leica cryomicrotome and ﬁxed with 4% paraformaldehyde. After
ﬁxation, sections were blocked with 10% fetal bovine serum in PBS,
and then stained overnight at 4 1C with a 1:200 dilution of mouse
monoclonal antibody against the LCMV NP. Tissues were washed
and incubated for 1 h at 4 1C with a 1:200 solution of Alexa Fluor
A.M. Lee et al. / Virology 442 (2013) 114–121 121488-conjugated anti-mouse IgG antibody (Life Technologies), and
were then washed and mounted using VectaShield mounting med-
ium (Vector Laboratories). Sections were imaged using a Zeiss
Axiovert S100 immunoﬂuorescence microscope ﬁtted with an Axio-
cam color digital camera and 20 and 40 objectives.
For immunoﬂuorescence staining of cells, cells were washed to
remove tissue culture medium and ﬁxed in 4% paraformaldehyde
for 10 min at room temperature. The cells were then blocked with
PBS/1% FBS/0.1% saponin buffer, and incubated overnight at 4 1C
with a 1:200 solution of anti-LCMV NP antibody. Cells were washed
three times with PBS/1% FBS/0.1% saponin and incubated for 1 h at
4 1C with a 1:200 solution of Alexa Fluor 488-coupled anti-mouse
IgG antibody. Cells were washed again and imaged using a 10x
objective on the Zeiss Axiovert immunoﬂuorescence microscope.Acknowledgments
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